Advertisement

Alternatives to Blood Products

  • James M. Kelley
Reference work entry

Abstract

Alternatives to blood products manage anemia and/or thrombocytopenia in patients while avoiding the risks of transfusion. Such strategies help preserve a limited blood supply, reduce exposure to donor blood products and possible transfusion reactions, and control financial costs related to blood. Alternatives can include improving blood production with nutrient supplementation or erythropoietin administration, using surgical techniques such as intraoperative cell salvage or acute normovolemic hemodilution, or administering pharmacologic agents to control bleeding such as antifibrinolytics and purified coagulation factors.

Keywords

Transfusion alternatives Patient blood management Iron supplementation Bloodless medicine Bloodless surgery 

References

  1. 1.
    Bennett CL, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008;299:914–24.  https://doi.org/10.1001/jama.299.8.914.CrossRefPubMedGoogle Scholar
  2. 2.
    Carson JL, et al. Clinical practice guidelines from the AABB: red blood cell transfusion thresholds and storage. JAMA. 2016a;316:2025–35.  https://doi.org/10.1001/jama.2016.9185.CrossRefPubMedGoogle Scholar
  3. 3.
    Carson JL, Stanworth SJ, Roubinian N, Fergusson DA, Triulzi D, Doree C, Hebert PC. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev. 2016b;10:CD002042.  https://doi.org/10.1002/14651858.CD002042.pub4.CrossRefPubMedGoogle Scholar
  4. 4.
    Crash- trial collaborators, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010;376:23–32.  https://doi.org/10.1016/S0140-6736(10)60835-5.CrossRefGoogle Scholar
  5. 5.
    Dutton RP, et al. Recombinant activated factor VII safety in trauma patients: results from the CONTROL trial. J Trauma. 2011;71:12–9.  https://doi.org/10.1097/TA.0b013e31821a42cf.CrossRefPubMedGoogle Scholar
  6. 6.
    Estcourt LJ, Desborough M, Brunskill SJ, Doree C, Hopewell S, Murphy MF, Stanworth SJ. Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders. Cochrane Database Syst Rev. 2016;3:CD009733.  https://doi.org/10.1002/14651858.CD009733.pub3.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Kaufman RM, et al. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med. 2015;162:205–13.  https://doi.org/10.7326/M14-1589.CrossRefPubMedGoogle Scholar
  8. 8.
    Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med. 2004;116(Suppl 7A):11S–26S.  https://doi.org/10.1016/j.amjmed.2003.12.008.CrossRefPubMedGoogle Scholar
  9. 9.
    Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med. 2010;363:1791–800.  https://doi.org/10.1056/NEJMoa1006221.CrossRefPubMedGoogle Scholar
  10. 10.
    Leyland-Jones B, et al. A randomized, open-label, multicenter, phase III study of epoetin alfa versus best standard of care in anemic patients with metastatic breast cancer receiving standard chemotherapy. J Clin Oncol. 2016;34:1197–207.  https://doi.org/10.1200/JCO.2015.63.5649.CrossRefPubMedGoogle Scholar
  11. 11.
    Ludwig H, et al. Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from the Anaemia Cancer Treatment (ACT) study. Eur J Cancer. 2009;45:1603–15.  https://doi.org/10.1016/j.ejca.2009.02.003.CrossRefPubMedGoogle Scholar
  12. 12.
    National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: cancer and chemotherapy related anemia vol version 2.2018. Bethesda; 2017.Google Scholar
  13. 13.
    Parameswaran R, Lunning M, Mantha S, Devlin S, Hamilton A, Schwartz G, Soff G. Romiplostim for management of chemotherapy-induced thrombocytopenia. Support Care Cancer. 2014;22:1217–22.  https://doi.org/10.1007/s00520-013-2074-2.CrossRefPubMedGoogle Scholar
  14. 14.
    Pfeffer MA, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019–32.  https://doi.org/10.1056/NEJMoa0907845.CrossRefPubMedGoogle Scholar
  15. 15.
    Price TH. The RING study: a randomized controlled trial of GCSF-stimulated granulocytes in granulocytopenic patients. Paper presented at the ASH 2014, San Francisco, CA; 2014.Google Scholar
  16. 16.
    Roback JD, et al. Evidence-based practice guidelines for plasma transfusion. Transfusion. 2010;50:1227–39.  https://doi.org/10.1111/j.1537-2995.2010.02632.x.CrossRefPubMedGoogle Scholar
  17. 17.
    Schiffer CA, et al. Platelet transfusion for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2018;36:283–99.  https://doi.org/10.1200/JCO.2017.76.1734.CrossRefPubMedGoogle Scholar
  18. 18.
    Slichter SJ, et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med. 2010;362:600–13.  https://doi.org/10.1056/NEJMoa0904084.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Svensson PJ, Bergqvist PB, Juul KV, Berntorp E. Desmopressin in treatment of haematological disorders and in prevention of surgical bleeding. Blood Rev. 2014;28:95–102.  https://doi.org/10.1016/j.blre.2014.03.001.CrossRefPubMedGoogle Scholar
  20. 20.
    Tonia T, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev. 2012;12:CD003407.  https://doi.org/10.1002/14651858.CD003407.pub5.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • James M. Kelley
    • 1
  1. 1.Department of Laboratory MedicineThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations